Date: 2014-08-06
Type of information: Licensing agreement
Compound: OX-MPI project
Company: Orexo (Sweden) Boehringer Ingelheim (Germany)
Therapeutic area: undisclosed
Type agreement: licensing agreement
Action mechanism:
Disease: undisclosed
Details: * On August 6, 2014, Orexo announcedthat Boehringer Ingelheim has decided to return the OX-MPI project to Orexo. The project aims to develop products based on specific inhibition of prostaglandin E2 (PGE2) in different disease conditions. Boehringer Ingelheim has since 2005 been responsible for all research and development within the OX-MPI project. Orexo is evaluating the results from Boehringer Ingelheim and when this is completed will make a final decision on the potential to continue the project with a new external partner. The return of OX-MPI from Boehringer Ingelheim has no direct impact on the financial position of Orexo. The OX-MPI project is associated with an intangible fixed asset of MSEK 62 from the acquisition of Biolipox and this asset will be impaired if a final decision is taken to discontinue the project.
Financial terms:
Latest news:
